Use of quinolones in the treatment of gastrointestinal infections.
Bacterial enteropathogens are responsible for between 40% and 80% of diarrheal illness depending upon the age of the persons affected and geographic areas where illness occurs. Antibacterial agents will shorten the illness associated with enteric infection caused by enterotoxigenic Escherichia coli, Shigella spp. and Campylobacter jejuni. These drugs also are effective in the therapy of certain clinical conditions (presumably because they are due to the same agents) which are characterized by moderate to severe diarrhea with one or more of the following: high fever, dysentery (passage of bloody mucoid stools), or high leukocyte counts in stools. Antimicrobial agents are also effective in the therapy of travelers' diarrhea. The quinolone drugs have several advantages in the management of bacterial diarrhea where strains causing illness from nearly all regions of the world will show general susceptibility: high concentrations are achieved in the intestinal lumen following oral administration and resistance development is unusual. A quinolone probably represents the optimal agent for therapy of bacterial diarrhea in adults in areas where trimethoprim-resistant enteric pathogens are common.
DuPont
H L
HL
Center for Infectious Diseases, University of Texas Health Science Center, Houston 77030.
D042462:4-Quinolones; D000890:Anti-Infective Agents / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D002169:Campylobacter Infections / Q000188:drug therapy*; D016123:Campylobacter jejuni / Q000187:drug effects; D003967:Diarrhea / Q000188:drug therapy*; D004405:Dysentery, Bacillary / Q000188:drug therapy; D004755:Enterobacteriaceae / Q000187:drug effects; D004756:Enterobacteriaceae Infections / Q000188:drug therapy*; D004927:Escherichia coli Infections / Q000188:drug therapy; D006801:Humans; D012480:Salmonella Infections / Q000188:drug therapy
D042462:4-Quinolones; D000890:Anti-Infective Agents